TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC Beta-CELL DYSFUNCTION AND FOR Beta-CELL PROLIFERATION
AssigneeDiaMedica Inc.
InventorsMark WILLIAMS, Kevin Richardson
Life of this patent
Estimating the term…
Abstract
The invention relates to methods of administering kallikrein, a variant, or active fragment thereof to stimulate proliferation of islet cells generally and β-cells specifically. The invention also includes compositions to stimulate proliferation in vivo and in vitro.
Claims8
A method of treating a human subject with β cell dysfunction comprising administering about 0.01 to about 100 IU per day of tissue kallikrein-1 (KLK1), a variant of active fragment thereof to about 100 the subject.
A method of stimulating β cell proliferation comprising contacting β cells with an effective amount of tissue kallikrein-1 (KLK1), a variant or active fragment thereof
A method of stimulating β cell proliferation in a subject comprising administering an effective amount of tissue kallikrein-1 (KLK1), a variant or active fragment thereof, wherein the subject is newly diagnosed with diabetes.
Dependencies are inferred from the claim text.